The new, minimally invasive outpatient procedure targets a part of the small intestine that plays a key role in diabetes.

Well-tolerated insulin sensitizer may play a role in the treatment of fatty liver disease.

Initial 12-week results of a 48-week treatment period showed the drug led to a significant decline in weight and liver enzymes.

Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.

Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.

The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.

This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.

The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.

This conference is for people who have a broad knowledge on and interest about NASH, NAFLD, steatohepatitis and fatty liver

Rising rates of obesity are fueling the epidemic.